FibroBiologics, Inc 8-K/A, filed Apr 9, 2026
FibroBiologics, Inc. (FBLG)
About this 8-K/A
FibroBiologics, Inc filed this 8-K/A on April 9, 2026, reporting on events of April 3, 2026.
Items reported
- Item 1.01: Entered into a material agreement
- Item 1.02: Ended a material agreement
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Explanatory Note
Item 1.01 Entry into a Material Definitive Agreement.
On April 3, 2026, FibroBiologics, Inc. (the “Company”) entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”) with United Fire & Casualty Co. (doing business as United Fire Group) (the “Sublandlord”) to terminate that certain Sublease Agreement, which was effective as of October 5, 2022 (“Sublease”), pursuant to which Sublandlord subleased to the Company certain premises located at the third floor of 455 E. Medical Center Blvd, Webster, County of Harris, Texas 77598. The Lease Termination Agreement terminated the Sublease effective April 2, 2026, successfully concluding the Sublease well ahead of its original expiration date of November 30, 2027. The Company resolved its remaining rent obligations with a single payment of $45,108.25 and expects to save approximately $0.8 million in future rent payments.
This strategic consolidation follows the Company's 2025 opening of its state-of-the-art laboratory facility, encompassing over 10,000 square feet of dedicated lab and office space. By eliminating redundant office costs approximately 18 months ahead of schedule, the Company strengthens its operational efficiency and redirects resources toward its core mission of advancing fibroblast-based therapeutics.
Item 1.02 Termination of a Material Definitive Agreement.
The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 1.02 by reference.
Item 8.01 Other Events.
The new address of the Company’s principal executive offices is 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
Item 9.01 Financial Statements and Exhibits.
Exhibit 104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
FibroBiologics, Inc. |
|
|
|
|
Date: |
Apri 9, 2026 |
By: |
/s/ Pete O'Heeron |
|
|
|
Name: Pete O'Heeron |